Objective：To determine the concentration of plasma soluble tumor necrosis factor-like weak inducer of apoptosis（sTWEAK） and serum high-sensitive C-reaction protein（hsCRP） in patients with acute coronary syndrome（ACS） and to investigate their clinical significance in the diagasis of ACS. Methods：A total of 62 patients with ACS（47 males and 15 females，（66.06±9.89） years old） treated in the department of cardiovascular diseases of the First Affiliated Hospital of Chongqing Medical university from September 1st 2012 to March 31st 2013 were involved in this study；19 patients with stable angina pectoris（SAP） confirmed by coronary angiog－raphy or CT were also analyzed；29 patients without coronary heart disease（CHD）in this period were served as control group. The 62 ACS patients were divided into 3 subgroups：ST-segment elevation myocardial infarction（STEMI） group（n=11），non ST-segment el－evation myocardial infarction（NSTEMI）group（n=14） and unstable angina pectoris（UAP） group（n=37）. The plasma sTWEAK was measured by enzyme-linked immunosorbent assay（ELISA） while serum hsCRP was determined by immunoturbidimetry. The concentrations of plasma sTWEAK and serum hsCRP were compared among ACS，SAP and control groups and also among the subgroups of ACS. The correlation between plasma sTWEAK and serum hsCRP，serum cTn were analyzed and plasma sTWEAK and serum hsCRP were compared between ctriple vessel disease and non-triple vessel disease in ACS group. Results：①The plasma sTWEAK concentration in ACS（139.95（121.30，155.51） ng/L） was significantly higher than that in SAP group（93.21（84.37，114.08） ng/L） and control group（124.24（118.32，135.49） ng/L）（P=0.000，P=0.007），and it was lower in SAP group than in control group（P=0.007）. ②The serum hsCRP concentration was significantly higher in ACS group（2.29（0.84，9.77） mg/L） than that in SAP group（1.40（0.47，1.96） mg/L） and control group（0.87（0.46，1.75） mg/L）（P=0.015，P=0.001），and there was no significant difference between SAP and control group（P=0.62）. ③There was no statistical difference in plasma sTWEAK level among the three subgroups of ACS（P=0.41）. The serum hsCRP concentration was higher in STEMI and NSTEMI subgroups than in UAP group（P=0.001，P=0.027），but without significant differences（P=0.202）. ④There was no linear correlation between plasma sTWEAK and serum hsCRP concen－tration（P=0.462） while serum hsCRP and cTn were positively correlated（r=0.578，P=0.000） and there was no difference in the plasma sTWEAK and serum hsCRP concentration between triple vessel disease and non-triple vessel disease. Conclusions：Patients with ACS have higher plasma sTWEAK and serum hsCRP concentrations when compared with SAP and non-CHD，demonstrating that sTWEAK and hsCRP may be helpful biochemical markers in the diagnosis of ACS.